{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-012856","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.598493+00:00","generated_at":"2026-06-25T21:03:52.621135+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oncocyte Q1 revenue $1.4M, net loss widens; CFO and Chairman transitions announced","bullets":["Q1 2022 total revenue $1.4M vs $1.1M YoY; DetermaRx revenue $1.0M.","Net loss $10.3M ($0.11 per share) vs net loss $3.9M ($0.05) a year ago.","Cash, equivalents & marketable securities $22.7M as of March 31, 2022.","Chairman Cavan Redmond not standing for reelection; Andrew Arno appointed Chairman effective May 6.","CFO Mitchell Levine to transition to Corporate Development Officer; Anish John named Interim CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-012856","json":"https://secwatch.observer/filing/0001493152-22-012856.json","markdown":"https://secwatch.observer/filing/0001493152-22-012856.md","text":"https://secwatch.observer/filing/0001493152-22-012856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:03:52.621135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c53f1aa10","claim":"Mitchell Levine changed role as Chief Financial Officer at Insight Molecular Diagnostics Inc..","evidence_excerpt":"Mitchell Levine, our Chief Financial Officer since 2017, will no longer serve in that capacity as of June 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"will no longer serve"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"3f8000963f","claim":"Cavan Redmond changed role as Chairman of the Board at Insight Molecular Diagnostics Inc..","evidence_excerpt":"Mr. Redmond has stepped down as Chairman of the Board, and that the Board has appointed Andrew Arno as Chairman of the Board effective May 6, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"8352daaacb","claim":"Andrew Arno was appointed as Chairman of the Board at Insight Molecular Diagnostics Inc..","evidence_excerpt":"the Board has appointed Andrew Arno as Chairman of the Board effective May 6, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"df86c14e6a","claim":"Anish John was appointed as Senior Vice President, Finance, and Interim Chief Financial Officer at Insight Molecular Diagnostics Inc..","evidence_excerpt":"Anish John, our Vice President, Operations – Transplant, has been appointed Senior Vice President, Finance, and Interim Chief Financial Officer effective June 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Finance, and Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}